Allist(SH:688578) Guolian Minsheng Securities·2026-02-01 09:59Investment Rating - The report gives a "Buy" rating for the company, indicating a positive outlook for its stock performance in the next 12 months [9]. Core Insights - The company is expected to achieve a revenue of 5.2 billion yuan in 2025, representing a year-on-year increase of 46.15% [2]. - The net profit attributable to shareholders is projected to be 2.15 billion yuan, reflecting a growth of 50.37% compared to the previous year [2]. - The growth is primarily driven by the company's focus on precision treatment for lung cancer, particularly through its commercialized product, Furmetinib, which has gained recognition in the industry [2]. - The company has optimized resource allocation and leveraged synergies among its commercial products, contributing to sustained operational performance [2]. Financial Projections - Revenue projections for 2025, 2026, and 2027 are 5.2 billion, 6.395 billion, and 8.193 billion yuan, respectively, with growth rates of 46.2%, 23.0%, and 28.1% [10]. - Net profit forecasts for the same years are 2.15 billion, 2.461 billion, and 3.187 billion yuan, with growth rates of 50.3%, 14.5%, and 29.5% [10]. - Earnings per share (EPS) are expected to be 4.78, 5.47, and 7.08 yuan for 2025, 2026, and 2027, respectively [10]. Product Development and Market Strategy - The company is actively conducting multiple clinical trials for Furmetinib, targeting various indications in non-small cell lung cancer (NSCLC), which is expected to provide growth momentum for its commercialization [3][4]. - The collaboration with ArriVent to develop Furmetinib for rare mutations in NSCLC is progressing well, with ongoing global Phase III clinical trials [3]. - The company has introduced additional products, such as Goretinib and Pralsetinib, enhancing its portfolio in the lung cancer treatment market [5][9]. Market Position and Competitive Advantage - The company has strengthened its commercialization capabilities, with a marketing team of over 1,400 personnel covering 31 provinces and more than 5,000 hospitals [8]. - All core products, including Furmetinib, Goretinib, and Pralsetinib, have been included in the new national medical insurance directory, effective January 1, 2026, which is expected to enhance market accessibility [8][9].